Get the Stockscreener App
90.73
0.86%
-0.8719
Edwards Lifesciences Corp stock is traded at $90.73, with a volume of 924.03K.
It is down -0.86% in the last 24 hours and up +5.93% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$91.60
Open:
$90.84
24h Volume:
924.03K
Relative Volume:
0.19
Market Cap:
$52.32B
Revenue:
$6.30B
Net Income/Loss:
$1.07B
P/E Ratio:
49.29
EPS:
1.8406
Net Cash Flow:
$1.09B
1W Performance:
-1.33%
1M Performance:
+5.93%
6M Performance:
+15.76%
1Y Performance:
+16.04%
1-Day Range:
$90.59
$91.58
1-Week Range:
$90.59
$93.91
52-Week Range:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
90.77 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
110.09 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
332.01 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.64 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.53 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Oppenheimer Asset Management Inc. Purchases Shares of 22,090 Edwards Lifesciences Corporation $EW - MarketBeat
AMG National Trust Bank Invests $6.83 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Maridea Wealth Management LLC Purchases New Position in Edwards Lifesciences Corporation $EW - MarketBeat
Bank Hapoalim BM Makes New $1.78 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Empowered Funds LLC Boosts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
ABN AMRO Bank N.V. Makes New $83.57 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Everett Harris & Co. CA Acquires Shares of 80,341 Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Seascape Capital Management's Edwards Lifesciences Corp(EW) Holding History - GuruFocus
Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock? - Yahoo Finance
Edwards Lifesciences CVP sells $56,966 in company stock By Investing.com - Investing.com Australia
Edwards Lifesciences CVP sells $56,966 in company stock - Investing.com
Edwards Lifesciences (EW) Insider Daniel Lippis Sells 619 Shares - GuruFocus
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Daniel Lippis Sells 619 Shares of Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences (EW) insider files Form 144 for cashless option exercise - Stock Titan
Handelsbanken Fonder AB Has $139.42 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
29,000 Shares in Edwards Lifesciences Corporation $EW Bought by Renaissance Technologies LLC - marketbeat.com
Edwards Lifesciences Corporation $EW is Seilern Investment Management Ltd's 4th Largest Position - MarketBeat
Orser Capital Management LLC Invests $2.32 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Assenagon Asset Management S.A. Acquires 547,212 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Fund Update: 525,889 EDWARDS LIFESCIENCES (EW) shares added to ABN AMRO Bank N.V. portfolio - Quiver Quantitative
Segall Bryant & Hamill LLC Acquires New Stake in Edwards Lifesciences Corporation $EW - MarketBeat
EW CLASS ACTION FINAL DEADLINE: Edwards Lifesciences Investors are Notified that Today is the Final Deadline in Securities Fraud Class Action and are Urged to Contact BFA Law - TMX Newsfile
Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match - Yahoo Finance
Is It Too Late to Buy Edwards Lifesciences Corp (EW) After 3.2% Rally? GF Value Says Undervalued - GuruFocus
Bank of America Corp DE Acquires 2,212,208 Shares of Edwards Lifesciences Corporation $EW - marketbeat.com
Groupama Asset Managment Purchases New Position in Edwards Lifesciences Corporation $EW - marketbeat.com
Empowered Funds LLC Increases Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
California State Teachers Retirement System Sells 34,344 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Liontrust Investment Partners LLP Trims Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Form 4 Edwards Lifesciences Corp For: 30 July By Investing.com - Investing.com Canada
Edwards Lifesciences Corp. stock rises Thursday, still underperforms market - MarketWatch
Edwards Lifesciences CVP Markowitz sells $12,587 of company stock - Investing.com
Edwards Lifesciences Corporation $EW Holdings Lifted by First Trust Advisors LP - MarketBeat
UBS initiates Edwards Lifesciences stock coverage with buy rating By Investing.com - Investing.com Nigeria
UBS Group Begins Coverage on Edwards Lifesciences (NYSE:EW) - MarketBeat
Form 4 Edwards Lifesciences Corp For: 27 July By Investing.com - Investing.com Nigeria
Edwards Lifesciences CEO Bernard Zovighian sells $245,134 in shares - Investing.com
Form 144 Edwards Lifesciences Corp For: 27 July By Investing.com - Investing.com South Africa
Form 144 Edwards Lifesciences Corp For: 27 July - Investing.com India
EW|Edwards Lifesciences Corp|Price:83.040|Chg%:+0.410 - TradingKey
Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion? - Yahoo Finance Singapore
Edwards Lifesciences (EW) insider Zovighian details recent $2.83M stock sale in Form 144 - Stock Titan
Edwards Lifesciences Corp (EW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edwards Lifesciences stock trades steady as TAVR growth supports margins - Ad-hoc-news.de
Edwards Lifesciences Corporation $EW Shares Purchased by Arrowstreet Capital Limited Partnership - MarketBeat
ETFs Investing in Edwards Lifesciences Corporation Stocks - TradingView
Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium - Yahoo Finance
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):